Elshaarawy Omar, Aman Aya, Zakaria Hazem Mohamed, Zakareya Talaat, Gomaa Asmaa, Elshimi Esam, Abdelsameea Eman
Department of Hepatology, Gastroenterology and Liver Transplantation, National Liver Institute, Menoufia University, Shebine Elkom 32511, Menoufia, Egypt.
Department of Hepatobiliary Pancreatic Surgery, National Liver Institute, Menoufia University, Shebine Elkom 32511, Menoufia, Egypt.
World J Gastrointest Oncol. 2021 May 15;13(5):424-439. doi: 10.4251/wjgo.v13.i5.424.
Given the poor synthetic function of cirrhotic liver, successful resection for patients with hepatocellular carcinoma (HCC) necessitates the ability to achieve resections with tumor free margins.
To validate post hepatectomy liver failure score (PHLF), compare it to other established systems and to stratify risks in patients with cirrhosis who underwent curative liver resection for HCC.
Between December 2010 and January 2017, 120 patients underwent curative resection for HCC in patients with cirrhosis were included, the pre-operative, operative and post-operative factors were recorded to stratify patients' risks of decompensation, survival, and PHLF.
The preoperative model for end-stage liver disease (MELD) score [odds ratio (OR) = 2.7, 95%CI: 1.2-5.7, = 0.013], tumor diameter (OR = 5.4, 95%CI: 2-14.8, = 0.001) and duration of hospital stay (OR = 2.5, 95%CI: 1.5-4.2, = 0.001) were significant independent predictors of hepatic decompensation after resection. While the preoperative MELD score [hazard ratio (HR) = 1.37, 95%CI: 1.16-1.62, < 0.001] and different grades of PHLF (grade A: HR = 2.33, 95%CI: 0.59-9.24; Grade B: HR = 3.15, 95%CI: 1.11-8.95; Grade C: HR = 373.41, 95%CI: 66.23-2105.43; < 0.001) and HCC recurrence (HR = 11.67, 95%CI: 4.19-32.52, < 0.001) were significant independent predictors for survival.
Preoperative MELD score and tumor diameter can independently predict hepatic decompensation. While, preoperative MELD score, different grades of PHLF and HCC recurrence can precisely predict survival.
鉴于肝硬化肝脏的合成功能较差,肝细胞癌(HCC)患者成功切除肿瘤需要能够实现切缘无肿瘤的切除。
验证肝切除术后肝功能衰竭评分(PHLF),将其与其他既定系统进行比较,并对接受根治性肝切除治疗HCC的肝硬化患者的风险进行分层。
2010年12月至2017年1月,纳入120例接受肝硬化患者HCC根治性切除的患者,记录术前、术中和术后因素,以对患者失代偿、生存和PHLF的风险进行分层。
术前终末期肝病模型(MELD)评分[比值比(OR)=2.7,95%置信区间:1.2 - 5.7,P = 0.013]、肿瘤直径(OR = 5.4,95%置信区间:2 - 14.8,P = 0.001)和住院时间(OR = 2.5,95%置信区间:1.5 - 4.2,P = 0.001)是切除术后肝失代偿的显著独立预测因素。而术前MELD评分[风险比(HR)=1.37,95%置信区间:1.16 - 1.62,P < 0.001]、不同等级的PHLF(A级:HR = 2.33,95%置信区间:0.59 - 9.24;B级:HR = 3.15,95%置信区间:1.11 - 8.95;C级:HR = 37,3.41,95%置信区间:66.